Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment Neuropsychiatric Disease and Treatment

: Schizophrenia is frequently a chronic and disabling disorder, characterized by heterogeneous positive and negative symptom constellations. The objective of this review was to provide information that may be useful for clinicians treating patients with negative symptoms of schizophrenia. Negative symptoms are a core component of schizophrenia that account for a large part of the long-term disability and poor functional outcomes in patients with the disorder. The term negative symptoms describes a lessening or absence of normal behaviors and functions related to motivation and interest, or verbal/emotional expression. The negative symptom domain consists of fi ve key constructs: blunted affect, alogia (reduction in quantity of words spoken), avolition (reduced goal-directed activity due to decreased motivation), asociality, and anhedonia (reduced experience of pleasure). Negative symptoms are common in schizophrenia; up to 60% of patients may have prominent clinically relevant negative symptoms that require treatment. Negative symptoms can occur at any point in the course of illness, although they are reported as the most common fi rst symptom of schizophrenia. Negative symptoms can be primary symptoms, which are intrinsic to the underlying pathophysiology of schizophrenia, or secondary symptoms that are related to psychiatric or medical comorbidities, adverse effects of treatment, or environmental factors. While secondary negative symptoms can improve as a consequence of treatment to improve symptoms in other domains (ie, positive symptoms, depressive symptoms or extrapyr-amidal symptoms), primary negative symptoms generally do not respond well to currently available antipsychotic treatment with dopamine D 2 antagonists or partial D 2 agonists. Since some patients may lack insight about the presence of negative symptoms, these are generally not the reason that patients seek clinical care, and clinicians should be especially vigilant for their presence. Negative symptoms clearly constitute an unmet medical need in schizophrenia, and new and effective treatments are urgently needed.

[1]  C. Correll,et al.  Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities , 2019, CNS Spectrums.

[2]  Anissa Abi-Dargham,et al.  Schizophrenia, Dopamine and the Striatum: From Biology to Symptoms , 2019, Trends in Neurosciences.

[3]  C. Correll,et al.  The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses , 2018, Therapeutic advances in psychopharmacology.

[4]  M. Cannon,et al.  Negative symptoms of psychosis: A life course approach and implications for prevention and treatment , 2018, Early intervention in psychiatry.

[5]  S. Galderisi,et al.  Negative symptoms of schizophrenia: new developments and unanswered research questions. , 2018, The lancet. Psychiatry.

[6]  C. Correll,et al.  Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia , 2018, Acta psychiatrica Scandinavica.

[7]  S. Leucht,et al.  Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis , 2018, European Archives of Psychiatry and Clinical Neuroscience.

[8]  S. Stahl Drugs for psychosis and mood: unique actions at D3, D2, and D1 dopamine receptor subtypes , 2017, CNS Spectrums.

[9]  I. Melle,et al.  Treatment of negative symptoms: Where do we stand, and where do we go? , 2017, Schizophrenia Research.

[10]  R. Luthringer,et al.  Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia. , 2017, The American journal of psychiatry.

[11]  C. Correll,et al.  Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in Schizophrenia: Systematic Overview and Quality Appraisal of the Meta-analytic Evidence , 2017, JAMA psychiatry.

[12]  V. Sohal,et al.  D3 Receptors Regulate Excitability in a Unique Class of Prefrontal Pyramidal Cells , 2017, The Journal of Neuroscience.

[13]  B. Kiss,et al.  Cariprazine Exhibits Anxiolytic and Dopamine D3 Receptor-Dependent Antidepressant Effects in the Chronic Stress Model , 2017, The international journal of neuropsychopharmacology.

[14]  P. Czobor,et al.  Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial , 2017, The Lancet.

[15]  S. Galderisi,et al.  The current conceptualization of negative symptoms in schizophrenia , 2017, World psychiatry : official journal of the World Psychiatric Association.

[16]  P. Sokoloff,et al.  The dopamine D3 receptor, a quarter century later , 2017, The European journal of neuroscience.

[17]  S. Leucht,et al.  Efficacy and Safety of Antidepressants Added to Antipsychotics for Schizophrenia: A Systematic Review and Meta-Analysis. , 2016, The American journal of psychiatry.

[18]  H. Häfner,et al.  Negative symptoms and their association with depressive symptoms in the long-term course of schizophrenia , 2016, European Archives of Psychiatry and Clinical Neuroscience.

[19]  S. Schulz,et al.  Dopamine D3 Receptors Inhibit Hippocampal Gamma Oscillations by Disturbing CA3 Pyramidal Cell Firing Synchrony , 2016, Front. Pharmacol..

[20]  J. Azorin,et al.  [Negative symptoms of schizophrenia: from electrophysiology to electrotherapy]. , 2015, L'Encephale.

[21]  J. Torous,et al.  Smartphone Apps for Schizophrenia: A Systematic Review , 2015, JMIR mHealth and uHealth.

[22]  E. Budtz-Jørgensen,et al.  Long-term trajectories of positive and negative symptoms in first episode psychosis: A 10year follow-up study in the OPUS cohort , 2015, Schizophrenia Research.

[23]  P. McGuire,et al.  Treatments of Negative Symptoms in Schizophrenia: Meta-Analysis of 168 Randomized Placebo-Controlled Trials. , 2015, Schizophrenia bulletin.

[24]  J. Mintz,et al.  A randomized pilot study of MOtiVation and Enhancement (MOVE) Training for negative symptoms in schizophrenia , 2015, Schizophrenia Research.

[25]  H. Möller,et al.  Pharmacological treatment of negative symptoms in schizophrenia , 2015, European Archives of Psychiatry and Clinical Neuroscience.

[26]  C. Correll,et al.  Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia , 2014, CNS Spectrums.

[27]  P. Chue,et al.  Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options , 2014, Neuropsychiatric disease and treatment.

[28]  G. Remington,et al.  Negative symptoms of schizophrenia: Clinical features, relevance to real world functioning and specificity versus other CNS disorders , 2014, European Neuropsychopharmacology.

[29]  Thomas Steckler,et al.  Negative symptoms of schizophrenia: Clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment , 2014, European Neuropsychopharmacology.

[30]  P. Cuijpers,et al.  Psychological interventions for psychosis: a meta-analysis of comparative outcome studies. , 2014, The American journal of psychiatry.

[31]  W. Gaebel,et al.  Negative symptoms, past and present: A historical perspective and moving to DSM-5 , 2014, European Neuropsychopharmacology.

[32]  M. Clarke,et al.  Do psychosis prodrome onset negative symptoms predict first presentation negative symptoms? , 2014, European Psychiatry.

[33]  D. Velligan,et al.  Integrated Psychosocial Treatment for Negative Symptoms , 2014 .

[34]  A. Kring,et al.  Psychosocial treatments for negative symptoms in schizophrenia: current practices and future directions. , 2013, Clinical psychology review.

[35]  S. Salomone,et al.  Dopamine D(3) receptor as a new pharmacological target for the treatment of depression. , 2013, European journal of pharmacology.

[36]  S. Kapur,et al.  Negative symptoms in schizophrenia – the remarkable impact of inclusion definitions in clinical trials and their consequences , 2013, Schizophrenia Research.

[37]  S. Marder,et al.  Association of prominent positive and prominent negative symptoms and functional health, well-being, healthcare-related quality of life and family burden: A CATIE analysis , 2013, Schizophrenia Research.

[38]  S. Marder,et al.  Pharmacological approaches to treating negative symptoms: A review of clinical trials , 2013, Schizophrenia Research.

[39]  D. Daniel Issues in Selection of Instruments to Measure Negative Symptoms , 2013, Schizophrenia Research.

[40]  S. Scuderi,et al.  Increased Hippocampal CREB Phosphorylation in Dopamine D3 Receptor Knockout Mice Following Passive Avoidance Conditioning , 2013, Neurochemical Research.

[41]  B. Kiss,et al.  Cariprazine, a dopamine D3-receptor-preferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mouse , 2013, Psychopharmacology.

[42]  C. Correll The Prevalence of Negative Symptoms in Schizophrenia and Their Impact on Patient Functioning and Course of Illness , 2013 .

[43]  R. Gur,et al.  The Clinical Assessment Interview for Negative Symptoms (CAINS): final development and validation. , 2013, The American journal of psychiatry.

[44]  J. Coyle NMDA receptor and schizophrenia: a brief history. , 2012, Schizophrenia bulletin.

[45]  Philip D. Harvey,et al.  Predicting the severity of everyday functional disability in people with schizophrenia: cognitive deficits, functional capacity, symptoms, and health status , 2012, World psychiatry : official journal of the World Psychiatric Association.

[46]  John M. Davis,et al.  Maintenance treatment with antipsychotic drugs for schizophrenia. , 2012, The Cochrane database of systematic reviews.

[47]  Tyrone D. Cannon,et al.  Negative symptoms in individuals at clinical high risk of psychosis , 2012, Psychiatry Research.

[48]  M. Millan,et al.  Selective Blockade of Dopamine D3 Receptors Enhances while D2 Receptor Antagonism Impairs Social Novelty Discrimination and Novel Object Recognition in Rats: A Key Role for the Prefrontal Cortex , 2012, Neuropsychopharmacology.

[49]  F. Chacón,et al.  Efficacy of lifestyle interventions in physical health management of patients with severe mental illness , 2011, Annals of general psychiatry.

[50]  W. Wölwer,et al.  Negative symptoms of schizophrenia as primary target of cognitive behavioral therapy: results of the randomized clinical TONES study. , 2011, Schizophrenia bulletin.

[51]  E. Walker,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[52]  D. Castillo,et al.  Interrater reliability of using brief standardized outcome measures in a community mental health setting. , 2011, Psychiatric services.

[53]  S. Marder,et al.  The brief negative symptom scale: psychometric properties. , 2011, Schizophrenia bulletin.

[54]  T. Barnes Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology , 2011, Journal of psychopharmacology.

[55]  Daniel Antonius,et al.  Avolition and expressive deficits capture negative symptom phenomenology: implications for DSM-5 and schizophrenia research. , 2011, Clinical psychology review.

[56]  Kyeong-Man Kim,et al.  Current perspectives on the selective regulation of dopamine D2 and D3 receptors , 2010, Archives of pharmacal research.

[57]  L. Alphs,et al.  The 4-Item Negative Symptom Assessment (NSA-4) Instrument: A Simple Tool for Evaluating Negative Symptoms in Schizophrenia Following Brief Training. , 2010, Psychiatry (Edgmont (Pa. : Township)).

[58]  Jonathan Y. Tsou RACHEL COOPER Classifying Madness: A Philosophical Examination of the Diagnostic and Statistical Manual of Mental Disorders , 2010, The British Journal for the Philosophy of Science.

[59]  J. Bobes,et al.  Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study. , 2010, The Journal of clinical psychiatry.

[60]  Gary Remington,et al.  Negative symptoms in schizophrenia: avolition and Occam's razor. , 2010, Schizophrenia bulletin.

[61]  D. Linszen,et al.  Baseline differences in clinical symptomatology between ultra high risk subjects with and without a transition to psychosis , 2009, Schizophrenia Research.

[62]  S. Leucht,et al.  How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials , 2009, Molecular Psychiatry.

[63]  P. Gorwood Neurobiological mechanisms of anhedonia , 2008, Dialogues in clinical neuroscience.

[64]  B. Kiss,et al.  Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. behavioural characterisation of RG-15 , 2008, Naunyn-Schmiedeberg's Archives of Pharmacology.

[65]  S. Stahl,et al.  Stahl's essential psychopharmacology : neuroscientific basis and practical application , 2008 .

[66]  M Isohanni,et al.  Negative symptoms in schizophrenia—A review , 2008, Nordic journal of psychiatry.

[67]  D. Javitt,et al.  The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. , 2007, The American journal of psychiatry.

[68]  R. Buchanan Persistent negative symptoms in schizophrenia: an overview. , 2007, Schizophrenia bulletin.

[69]  J. Coyle,et al.  Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis , 2006, Cellular and Molecular Neurobiology.

[70]  Brian Kirkpatrick,et al.  The NIMH-MATRICS consensus statement on negative symptoms. , 2006, Schizophrenia bulletin.

[71]  B. Kirkpatrick,et al.  Subdomains within the negative symptoms of schizophrenia: commentary. , 2006, Schizophrenia bulletin.

[72]  M. Millan,et al.  Dopamine D3 receptor antagonists as therapeutic agents. , 2005, Drug discovery today.

[73]  I. Laszlovszky,et al.  Dopamine D3 receptor antagonists improve the learning performance in memory-impaired rats , 2005, Psychopharmacology.

[74]  N. Andreasen,et al.  Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. , 2005, The American journal of psychiatry.

[75]  P. Sokoloff,et al.  Neuroadaptations to hyperdopaminergia in dopamine D3 receptor-deficient mice. , 2005, Life sciences.

[76]  H. Tsukada,et al.  N-methyl-d-aspartate antagonists as drug models of schizophrenia: a surprising link to tobacco smoking , 2004, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[77]  Anissa Abi-Dargham,et al.  Do we still believe in the dopamine hypothesis? New data bring new evidence. , 2004, The international journal of neuropsychopharmacology.

[78]  D. Javitt,et al.  Comparative effects of glycine and d-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis , 2004, Schizophrenia Research.

[79]  J. Hagan,et al.  Selective Antagonism at Dopamine D3 Receptors Enhances Monoaminergic and Cholinergic Neurotransmission in the Rat Anterior Cingulate Cortex , 2003, Neuropsychopharmacology.

[80]  R. Wightman,et al.  Dopamine autoreceptor regulation of release and uptake in mouse brain slices in the absence of D3 receptors , 2002, Neuroscience.

[81]  J. Coyle,et al.  The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. , 2001, The American journal of psychiatry.

[82]  R. Buchanan,et al.  A separate disease within the syndrome of schizophrenia. , 2001, Archives of general psychiatry.

[83]  F. J. White,et al.  Alterations in Dopamine Release But Not Dopamine Autoreceptor Function in Dopamine D3 Receptor Mutant Mice , 1998, The Journal of Neuroscience.

[84]  W. Eaton,et al.  Ten‐year course of schizophrenia—the Madras longitudinal study , 1994, Acta psychiatrica Scandinavica.

[85]  D. Javitt,et al.  Amelioration of negative symptoms in schizophrenia by glycine. , 1994, The American journal of psychiatry.

[86]  R. Goldman,et al.  Validation of the 16-item Negative Symptom Assessment. , 1993, Journal of psychiatric research.

[87]  P. Kulhara,et al.  Positive and negative subtypes of schizophrenia A follow-up study from India , 1990, Schizophrenia Research.

[88]  N. Andreasen The Scale for the Assessment of Negative Symptoms (SANS): Conceptual and Theoretical Foundations , 1989, British Journal of Psychiatry.

[89]  J. Lindenmayer,et al.  Negative and positive schizophrenic syndromes after the acute phase: a prospective follow-up. , 1986, Comprehensive psychiatry.

[90]  J. Geddes,et al.  60 years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis and meta-regression of efficacy predictors , 2017 .

[91]  R. Salvador,et al.  Cognitive-behavioural therapy for the symptoms of schizophrenia: systematic review and meta-analysis with examination of potential bias. , 2014, The British journal of psychiatry : the journal of mental science.

[92]  Paul M. Grant,et al.  Dysfunctional attitudes and expectancies in deficit syndrome schizophrenia. , 2013, Schizophrenia bulletin.

[93]  E. Torrey,et al.  Adjunct treatments for schizophrenia and bipolar disorder: what to try when you are out of ideas. , 2012, Clinical schizophrenia & related psychoses.

[94]  Vyv Huddy,et al.  A Meta-Analysis of Cognitive Remediation for Schizophrenia: Methodology and Effect Sizes , 2012 .

[95]  P. Buckley Prevalence of Negative Symptoms in Outpatients With Schizophrenia Spectrum Disorders Treated With Antipsychotics in Routine Clinical Practice: Findings From the CLAMORS Study , 2011 .

[96]  P. Sokoloff,et al.  Dopamine and glutamate dysfunctions in schizophrenia: Role of the dopamine D3 receptor , 2009, Neurotoxicity Research.

[97]  É. Schmidt,et al.  Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: I. neurochemical characterisation of RG-15 , 2008, Naunyn-Schmiedeberg's Archives of Pharmacology.

[98]  H. Häfner,et al.  The epidemiology of onset and course of schizophrenia , 2000, European Archives of Psychiatry and Clinical Neuroscience.

[99]  S. Kay,et al.  The positive and negative syndrome scale (PANSS) for schizophrenia. , 1987, Schizophrenia bulletin.

[100]  M. Harrow,et al.  Negative symptoms in schizophrenia: their longitudinal course and prognostic importance. , 1985, Schizophrenia bulletin.